{
    "pmid": "41468824",
    "title": "Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study.",
    "abstract": "Older adults with ovarian cancer often receive modified chemotherapy regimens due to concerns about treatment-related toxicity. This retrospective study compares feasibility, efficacy, and safety between a fractionated carboplatin-paclitaxel regimen (carboplatin on day 1 and paclitaxel on days 1 and 8) and the standard every-3-week regimen in patients aged â‰¥70 years. We conducted a single-center retrospective analysis of 102 patients treated with fractionated or standard carboplatin-paclitaxel at Georges Pompidou European Hospital (Paris, France) between 2015 and 2023. The primary end point was treatment feasibility, defined as completion of 6 chemotherapy cycles without premature discontinuation, unplanned hospital admission, significant delay or dose reduction due to toxicity, progression, or death. Secondary end points included progression-free survival, overall survival, and treatment-related adverse events. Of the 102 patients, 58 received standard and 44 received fractionated carboplatin-paclitaxel. Treatment was feasible in 72% versus 57% of patients receiving the standard or fractionated regimens, respectively (p = .10). Among patients treated in the first-line setting, median progression-free survival was 18 months with the standard regimen and 24 months with the fractionated regimen (p = .36); median overall survival was 71 and 48 months, respectively (p = .36). Overall toxicity rates were similar between groups, but fractionated carboplatin-paclitaxel was associated with a lower rate of grade 2 to 4 sensory neuropathy (16% vs 41%, p = .01) and a higher rate of grade 3 to 4 anemia (26% vs 5%, p = .008). Both standard and fractionated carboplatin-paclitaxel regimens appear feasible and yield similar survival outcomes in older patients with ovarian cancer. A fractionated regimen may offer reduced neurotoxicity. These findings warrant prospective evaluation of fractionated carboplatin-paclitaxel in older adults and in other tumor types, including cervical, endometrial, and lung cancer, particularly in combination with immune checkpoint inhibitors.",
    "disease": "breast cancer",
    "clean_text": "feasibility of standard versus fractionated carboplatin paclitaxel in older adults with ovarian cancer a retrospective study older adults with ovarian cancer often receive modified chemotherapy regimens due to concerns about treatment related toxicity this retrospective study compares feasibility efficacy and safety between a fractionated carboplatin paclitaxel regimen carboplatin on day and paclitaxel on days and and the standard every week regimen in patients aged years we conducted a single center retrospective analysis of patients treated with fractionated or standard carboplatin paclitaxel at georges pompidou european hospital paris france between and the primary end point was treatment feasibility defined as completion of chemotherapy cycles without premature discontinuation unplanned hospital admission significant delay or dose reduction due to toxicity progression or death secondary end points included progression free survival overall survival and treatment related adverse events of the patients received standard and received fractionated carboplatin paclitaxel treatment was feasible in versus of patients receiving the standard or fractionated regimens respectively p among patients treated in the first line setting median progression free survival was months with the standard regimen and months with the fractionated regimen p median overall survival was and months respectively p overall toxicity rates were similar between groups but fractionated carboplatin paclitaxel was associated with a lower rate of grade to sensory neuropathy vs p and a higher rate of grade to anemia vs p both standard and fractionated carboplatin paclitaxel regimens appear feasible and yield similar survival outcomes in older patients with ovarian cancer a fractionated regimen may offer reduced neurotoxicity these findings warrant prospective evaluation of fractionated carboplatin paclitaxel in older adults and in other tumor types including cervical endometrial and lung cancer particularly in combination with immune checkpoint inhibitors"
}